Reducing hallucinations in schizophrenia with focused ultrasound: First-in-human clinical trial begins

by Focused Ultrasound Foundation

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

The GIST Add to Preferred Sources

Auditory hallucinations—or hearing voices that others do not hear—affect more than 70% of people with schizophrenia. Despite treatment with antipsychotic medications, approximately 40% continue to experience persistent hallucinations. For these patients, new treatment approaches are urgently needed.

The research team at the University of California San Francisco (UCSF), led by Karuna Subramaniam, Ph.D., a professor of psychiatry, has launched a first-in-human Phase I clinical trial to evaluate the safety and feasibility of repeated low-intensity focused ultrasound (LIFU) sessions targeting the caudate, a deep brain region within the striatum that may play a role in hallucinations. The team is using a noninvasive wearable device developed by Attune Neurosciences.

Enrollment is underway to investigate whether repeated treatments can produce sustained reductions in hallucinations. The trial builds on encouraging preliminary findings published in Brain Stimulation, which demonstrated that a single session of LIFU produced significant, albeit temporary, reductions in hallucinations.

The study plans to enroll up to 12 participants. Each participant will receive five daily sessions of active LIFU targeting the caudate and five sessions of a sham control (unfocused sonication), with a washout period between conditions.

The unfocused control condition delivers the same amount of ultrasound energy and is designed to preserve the sensory experience of treatment, but without focusing ultrasound energy on a specific brain target. Comparing the two conditions will help researchers evaluate whether active LIFU reduces hallucination symptoms beyond any placebo or other nonspecific treatment effects.

Resting-state functional MRI will be obtained before and after treatment to examine changes in functional connectivity between the caudate and other brain regions. Clinical outcomes will include validated measures of auditory hallucination severity, other psychiatric symptoms and mood. The study will also evaluate treatment safety, tolerability and potential side effects.

"For many people with schizophrenia, hearing voices remains a persistent and distressing problem despite medication," said Subramaniam. "Our goal is to determine whether LIFU can safely and noninvasively target the caudate, a deep brain region that may play a role in the emergence of hallucinations, and offer a new treatment approach to reducing these symptoms."

Initial participants in the ongoing trial have reported reductions in hallucinations following repeated LIFU. One participant described the experience by saying, "I'm so surprised the voices have gone for now. My mind is really quiet."

Another participant, who had been hearing voices constantly, described their experience before treatment: "Hours can pass, and I feel like I lose track of time when I hear the voices and they seem to originate from outside and insert thoughts in my head." After treatment, the participant remarked with laughter, "I did hear one voice saying, 'I'm still here,' but the voices are softer, more like in the distant background, and seem to be going away. I feel it's very peaceful."

These early observations are preliminary but encouraging. As enrollment continues, the study will investigate whether repeated LIFU treatments can produce more sustained reductions in hallucinations and whether similar benefits are observed in additional participants.

A similar clinical trial was published in npj Acoustics, where researchers at NYU Langone Health used a different focused ultrasound device to target the globus pallidus region of the brain in patients with schizophrenia or schizoaffective disorder. They noted a modest but clear reduction in delusions among the participants.

More information

Karuna Subramaniam et al., Low-intensity focused ultrasound targeting striatal circuits in schizophrenia: feasibility, safety, and effects on hallucinations and striatal-temporal functional connectivity, Brain Stimulation (2026). DOI: 10.1016/j.brs.2026.103084

Key medical concepts

Auditory HallucinationSchizophreniaCaudate Nucleus

Clinical categories

PsychiatryPsychology & Mental health Provided by Focused Ultrasound Foundation Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Reducing hallucinations in schizophrenia with focused ultrasound: First-in-human clinical trial begins (2026, November 2) retrieved 3 November 2026 from https://medicalxpress.com/news/2026-11-hallucinations-schizophrenia-focused-ultrasound-human.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.